Long-term durability of immunogenicity induced by standard and triple-dose hepatitis B vaccine in patients receiving methadone maintenance treatment

References

• Organization WH. Global hepatitis report, 2017 (2017).
   Google Scholar
• Tan Y-J. Hepatitis B virus infection and the risk of hepatocellular carcinoma. World J Gastroenterol. 2011;17(44):4853.
   PubMed Web of Science ®Google Scholar
• Nayagam S, Thursz M, Sicuri E, et al. Requirements for global elimination of hepatitis B: a modelling study. Lancet Infect Dis. 2016;16(12):1399–1408.
   PubMed Web of Science ®Google Scholar
• Wilson N, lecturer S. Preventing and treating hepatitis B infection. Bmj Chin Ed. 2007;334(7584):96.
   Google Scholar
• Xiaofeng L, Shengli B, Weizhong Y, et al. Epidemiological serosurvey of hepatitis B in China–declining HBV prevalence due to hepatitis B vaccination. Vaccine. 2009;27(47):6550–6557.
   PubMed Web of Science ®Google Scholar
• Razavi-Shearer D, Gamkrelidze I, Nguyen MH. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3(6):383–403.
   PubMed Web of Science ®Google Scholar
• Lei Z, CEP F, Xun Z, et al. Methadone maintenance treatment participant retention and behavioural effectiveness in China: a systematic review and meta-analysis. Plos One. 2013;8(7):e68906.
   PubMed Web of Science ®Google Scholar
• Degenhardt L, Peacock A, Colledge S, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health. 2017;5(12):S2214109X17303753.
   Web of Science ®Google Scholar
• Luo X, Zhao P, Gong X, et al. Concurrent heroin use and correlates among methadone maintenance treatment clients: a 12-month follow-up study in Guangdong Province, China. Int J Environ Res Public Health. 2016;13(3):305.
   Web of Science ®Google Scholar
• Wang PW, Lin HC, Yen CN, et al. Comparison of outcomes after 3-month methadone maintenance treatment between heroin users with and without HIV infection: a 3-month follow-up study. Harm Reduct J. 2015;12(1):13.
   PubMedGoogle Scholar
• Chen W, Xia Y, Hong Y, et al. Predictors of continued HIV-risk behaviors among drug users in methadone maintenance therapy program in China—A prospective study. Harm Reduct J. 2013;10(1):23.
   PubMedGoogle Scholar
• Zou X, Xu Y, Chen W, et al. Strategies to control HIV and HCV in methadone maintenance treatment in Guangdong Province, China: a system dynamic modeling study. Subst Abuse Treat Prev Policy. 2018;13(1):1.
   PubMedGoogle Scholar
• Russolillo A, Moniruzzaman A, Somers JM. Methadone maintenance treatment and mortality in people with criminal convictions: a population-based retrospective cohort study from Canada. PLoS Med. 2018;15(7):e1002625.
   PubMed Web of Science ®Google Scholar
• Sacerdote P, Franchi S, Gerra G, et al. Buprenorphine and methadone maintenance treatment of heroin addicts preserves immune function. Brain Behav Immun. 2008;22(4):606–613.
   PubMed Web of Science ®Google Scholar
• Yuan-Yu C, Szu-Nian Y, Jyh-Chyang L, et al. Inflammatory response in heroin addicts undergoing methadone maintenance treatment. Psychiatry Res. 2015;226(1):230–234.
   PubMed Web of Science ®Google Scholar
• Parameswaran R, Nicholas L, Yvonne S, et al. The outcome of a rapid hepatitis B vaccination programme in a methadone treatment clinic. Addiction. 2010;105(2):329–334.
   PubMed Web of Science ®Google Scholar
• Hou J, Wang G, Wang F, et al. Guideline of prevention and treatment for chronic hepatitis B (2015 Update). J. clin. transl. hepatol. 2017;5(4):297–318.
   Google Scholar
• Pan HX, Zeng Y, Song X-F, et al. Immune response to hepatitis B vaccine with high antigen content in non-responders after standard primary vaccination in Chinese adults. Vaccine. 2014;32(29): 3706–3712.
   PubMed Web of Science ®Google Scholar
• Feng Y, Shi X, Shi J, et al. Immunogenicity, antibody persistence, and safety of the 60 μg hepatitis B vaccine in hemodialysis patients: a multicenter, randomized, double-blind, parallel-controlled trial. Expert Rev Vaccines. 2017;16(10): 1045–1052.
   PubMed Web of Science ®Google Scholar
• ZZ W, MQ L, W P, et al. Comparative immunogenicity of hepatitis B vaccine with different dosages and schedules in healthy young adults in China. Vaccine. 2016;34(8):1034–1039.
   PubMed Web of Science ®Google Scholar
• Shi J, Feng Y, Gao L, et al. Immunogenicity and safety of a high-dose hepatitis B vaccine among patients receiving methadone maintenance treatment: A randomized, double-blinded, parallel-controlled trial. Vaccine. 2017;35(18): 2443–2448.
   PubMed Web of Science ®Google Scholar
• Verso C, Vitale A. Immunization against hepatitis B surface antigen (hbsag) in a cohort of nursing students two decades after vaccination: surprising feedback. Vaccines (Basel). 2019;8(1):1.
   Web of Science ®Google Scholar
• O’Bryan TA, Rini EA, Jf O, et al. HIV viraemia during hepatitis B vaccination shortens the duration of protective antibody levels. HIV Med. 2015;16(3):161–167.
   PubMed Web of Science ®Google Scholar
• Shah DP, Grimes CZ, Nguyen AT, et al. Long-term effectiveness of accelerated hepatitis B vaccination schedule in drug users. Am J Public Health. 2015;105(6):e36.
   PubMed Web of Science ®Google Scholar
• Vania Baptista L, Hassing RJ, De Vries-Sluijs TEMS, et al. Long-term response rates of successful hepatitis B vaccination in HIV-infected patients. Vaccine. 2013;31(7):1040–1044.
   PubMed Web of Science ®Google Scholar
• CFDA. The standard guidelines for adverse reactions grading of vaccine clinical trials. Eds. (China Food and Drug Administration)
   Google Scholar
• LY H, CZ G, TQ T, et al. Accelerated hepatitis B vaccination schedule among drug users: a randomized controlled trial. J Infect Dis. 2010;202(10):1500–1509.
   PubMed Web of Science ®Google Scholar
• AA A, M M, N Z, et al. Vaccination against hepatitis B among prisoners in Iran: accelerated vs. classic vaccination. Health policy (Amsterdam, Netherlands). 2011;100:297–304.
   PubMed Web of Science ®Google Scholar
• GR K, DP S, LY H. Immune response to hepatitis B vaccination in drug using populations: a systematic review and meta-regression analysis. Vaccine. 2014;32(20):2265–2274.
   PubMed Web of Science ®Google Scholar
• TQ T, G CZ, L D, et al. Effect of age and frequency of injections on immune response to hepatitis B vaccination in drug users. Vaccine. 2012;30(2):342–349.
   PubMed Web of Science ®Google Scholar
• Solen K, Odile L, Clément T, et al. Long-term immune responses to vaccination in HIV-infected patients: a systematic review and meta-analysis. Clin Infect Dis Off Publ Infect Dis Soc Am. 2014;58(8): 1130–1139.
   PubMed Web of Science ®Google Scholar
• R D, P L, W MJ, et al. Safety and immunogenicity of double-dose versus standard-dose hepatitis B revaccination in non-responding adults with HIV-1 (ANRS HB04 B-BOOST): a multicentre, open-label, randomised controlled trial. Lancet Infect Dis. 2015;15(11): 1283–1291.
   PubMed Web of Science ®Google Scholar
• Launay O, Rosenberg AR, Rey D, et al. Long-term immune response to hepatitis B virus vaccination regimens in adults with human immunodeficiency virus 1: secondary analysis of a randomized clinical trial. JAMA Intern Med. 2016;176(5): 5.
   Web of Science ®Google Scholar
• Gesemann M, Scheiermann N, Gilks W. Hepatitis B vaccine boosting among young healthy adults. Lancet. 1995;345(8946):395–396.
   PubMed Web of Science ®Google Scholar
• Jilg W, Schmidt M, Deinhardt F. Decline of anti-HBs after hepatitis B vaccination and timing of revaccination. Lancet. 1990;335(8682):173–174.
   PubMed Web of Science ®Google Scholar
• Chrisikos TT, Zhou Y, Slone N, et al. Molecular regulation of dendritic cell development and function in homeostasis, inflammation, and cancer. Mol Immunol. 2019(110):24–39..
   Web of Science ®Google Scholar
• Bian G, Cheng Y, Wang Z, et al. Whole recombinant Hansenula polymorpha expressing hepatitis B virus surface antigen (yeast-HBsAg) induces potent HBsAg-specific Th1 and Th2 immune responses. Vaccine. 2010;28(1):187–194.
   Web of Science ®Google Scholar
• Gasim GI, Bella A, Adam I. Immune response to hepatitis B vaccine among patients on hemodialysis. World J Hepatol. 2015;7(2):270–275.
   PubMed Web of Science ®Google Scholar
• Grzegorzewska AE. Hepatitis B vaccination in chronic kidney disease patients: a call for novel vaccines. Expert Rev Vaccines. 2014;13(11):1317–1326.
   PubMed Web of Science ®Google Scholar
• Shouval D, Roggendorf H, Roggendorf M. Enhanced immune response to hepatitis B vaccination through immunization with a Pre-S1/Pre-S2/S vaccine. Med Microbiol Immunol. 2015;204(1):57–68.
   PubMed Web of Science ®Google Scholar
• Carina R, Bovin NV, Lone Valentin B, et al. Age is an important determinant in humoral and T cell responses to immunization with hepatitis B surface antigen. Hum Vaccin Immunother. 2013;9(7):1466–1476.
   PubMed Web of Science ®Google Scholar